FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2949859621> ?p ?o ?g. }

• W2949859621 endingPage "218" @default.
• W2949859621 startingPage "217" @default.
• W2949859621 abstract "Introduction: The Phase 3 RIAltO trial opened in December 2011 to compare ofatumumab plus chlorambucil (O+C) with ofatumumab plus bendamustine (O+B) in patients with previously untreated chronic lymphocytic leukaemia (CLL) considered unfit for FCR (fludarabine, cyclophosphamide, rituximab). The protocol was amended in September 2014 to investigate the addition of idelalisib (first-in-class inhibitor of the p110δ isoform of phosphoinositol-3 kinase) or placebo. However, all idelalisib/placebo treatment was withdrawn from the trial in March 2016 following safety analysis of idelalisib registration studies and recommendations from Gilead Sciences Ltd and regulatory authorities. Here, we present an updated ad-hoc analysis of the cohort of patients in RIAltO who received idelalisib or placebo. Methods: Patients were eligible for inclusion if they had previously untreated CLL requiring treatment by NCI/IWCLL criteria, were considered unfit for FCR and did not have any contraindications to the study drugs. Consenting patients underwent an unblinded 1:1 randomisation to ofatumumab (300mg iv day 1 and 1000mg iv day 8 of cycle 1; 1000mg iv day 1 of cycle 2 onwards) plus either chlorambucil (10mg/m2 day 1-7, repeated every 28 days for 3-12 cycles) or bendamustine (70mg/m2 iv day 1-2 for 3-6 cycles) and a double-blinded 1:1 randomisation to concurrently administered placebo or idelalisib (150mg bd for up to 3 years). Co-trimoxazole prophylaxis was recommended. Study drugs were discontinued in the event of disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). The mandatory post-treatment reporting period for serious adverse events (SAEs) was 6 months for grade ≥3 infections and 28 days for other events. Results: 145 patients received idelalisib (73) or placebo (72), the two arms being well balanced for age, gender, stage, co-morbidity, performance status and chemotherapy allocation. The median idelalisib exposure time was 3.3 months (IQR 1.2-7.3 months). As of January 2019, SAEs were reported in 79% of idelalisib-treated patients (87 grade 3-4 and 9 grade 5) compared to 50% of the placebo arm (38 grade 3-4 and 6 grade 5). The frequency of SAEs in the idelalisib arm was similar in both chemotherapy groups. After a median follow-up of 41.7 months (IQR 36.2-45.4 months), 28 PFS events have been reported in the idelalisib arm compared with 39 in the placebo arm (P = 0.070, log-rank test), while 10 and 16 deaths have been observed in the idelalisib and placebo arms, respectively (P = 0.218, log-rank test). Although 6-month mortality in the idelalisib arm was twice that of the placebo arm, only 2 deaths have been reported beyond 6 months in the idelalisib arm compared with 12 in the placebo arm. Keywords: chronic lymphocytic leukemia (CLL); idelalisib; ofatumumab. Disclosures: Pettitt, A: Research Funding: Celgene, Chugai, Gilead, GSK/Novartis, Roche, Verastem; Other Remuneration: Celgene, Gilead. Kalakonda, N: Research Funding: Celgene. Schuh, A: Consultant Advisory Role: Gilead, Abbvie, Janssen, Roche; Honoraria: Gilead, Abbvie, Janssen, Roche; Research Funding: Gilead and Janssen. Duncombe, A: Honoraria: Abbvie, Novartis, Gilead, Janssen. Paneesha, S: Honoraria: Speaker Fee Janssen, Gilead, Abbvie. Fox, C: Consultant Advisory Role: Abbvie, Adienne, Celgene, Gilead, Janssen, Roche, Takeda, Sunesis, Atarabio; Honoraria: Abbvie, Adienne, Celgene, Gilead, Janssen, Roche, Takeda, Sunesis, Atarabio; Research Funding: Abbvie, Adienne, Gilead, Roche. Hamblin, M: Honoraria: Roche. Hillmen, P: Honoraria: Janssen, Abbvie, Roche; Research Funding: Janssen, Pharmacyclics, Abbvie, Roche, Gilead." @default.
• W2949859621 created "2019-06-27" @default.
• W2949859621 creator A5001374433 @default.
• W2949859621 creator A5001501572 @default.
• W2949859621 creator A5006323887 @default.
• W2949859621 creator A5006812245 @default.
• W2949859621 creator A5009133053 @default.
• W2949859621 creator A5014125875 @default.
• W2949859621 creator A5014885875 @default.
• W2949859621 creator A5030982497 @default.
• W2949859621 creator A5033024327 @default.
• W2949859621 creator A5038369667 @default.
• W2949859621 creator A5043908553 @default.
• W2949859621 creator A5047631289 @default.
• W2949859621 creator A5048983223 @default.
• W2949859621 creator A5050927092 @default.
• W2949859621 creator A5053444316 @default.
• W2949859621 creator A5064560665 @default.
• W2949859621 creator A5066232993 @default.
• W2949859621 creator A5074839524 @default.
• W2949859621 creator A5080546745 @default.
• W2949859621 creator A5082526059 @default.
• W2949859621 creator A5086652821 @default.
• W2949859621 creator A5089155085 @default.
• W2949859621 date "2019-06-01" @default.
• W2949859621 modified "2023-09-23" @default.
• W2949859621 title "BRIEF CO-ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONG-TERM EFFICACY OF FRONTLINE CHEMOIMMUNOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKAEMIA: 3-YEAR FOLLOW-UP FROM THE RIALTO TRIAL" @default.
• W2949859621 doi "https://doi.org/10.1002/hon.32_2630" @default.
• W2949859621 hasPublicationYear "2019" @default.
• W2949859621 type Work @default.
• W2949859621 sameAs 2949859621 @default.
• W2949859621 citedByCount "0" @default.
• W2949859621 crossrefType "journal-article" @default.
• W2949859621 hasAuthorship W2949859621A5001374433 @default.
• W2949859621 hasAuthorship W2949859621A5001501572 @default.
• W2949859621 hasAuthorship W2949859621A5006323887 @default.
• W2949859621 hasAuthorship W2949859621A5006812245 @default.
• W2949859621 hasAuthorship W2949859621A5009133053 @default.
• W2949859621 hasAuthorship W2949859621A5014125875 @default.
• W2949859621 hasAuthorship W2949859621A5014885875 @default.
• W2949859621 hasAuthorship W2949859621A5030982497 @default.
• W2949859621 hasAuthorship W2949859621A5033024327 @default.
• W2949859621 hasAuthorship W2949859621A5038369667 @default.
• W2949859621 hasAuthorship W2949859621A5043908553 @default.
• W2949859621 hasAuthorship W2949859621A5047631289 @default.
• W2949859621 hasAuthorship W2949859621A5048983223 @default.
• W2949859621 hasAuthorship W2949859621A5050927092 @default.
• W2949859621 hasAuthorship W2949859621A5053444316 @default.
• W2949859621 hasAuthorship W2949859621A5064560665 @default.
• W2949859621 hasAuthorship W2949859621A5066232993 @default.
• W2949859621 hasAuthorship W2949859621A5074839524 @default.
• W2949859621 hasAuthorship W2949859621A5080546745 @default.
• W2949859621 hasAuthorship W2949859621A5082526059 @default.
• W2949859621 hasAuthorship W2949859621A5086652821 @default.
• W2949859621 hasAuthorship W2949859621A5089155085 @default.
• W2949859621 hasConcept C126322002 @default.
• W2949859621 hasConcept C142724271 @default.
• W2949859621 hasConcept C204787440 @default.
• W2949859621 hasConcept C27081682 @default.
• W2949859621 hasConcept C2776694085 @default.
• W2949859621 hasConcept C2776755627 @default.
• W2949859621 hasConcept C2777607594 @default.
• W2949859621 hasConcept C2777866208 @default.
• W2949859621 hasConcept C2777938653 @default.
• W2949859621 hasConcept C2778461978 @default.
• W2949859621 hasConcept C2778714382 @default.
• W2949859621 hasConcept C2779260929 @default.
• W2949859621 hasConcept C2779263901 @default.
• W2949859621 hasConcept C2779338263 @default.
• W2949859621 hasConcept C2779878957 @default.
• W2949859621 hasConcept C2780653079 @default.
• W2949859621 hasConcept C2781442060 @default.
• W2949859621 hasConcept C71924100 @default.
• W2949859621 hasConceptScore W2949859621C126322002 @default.
• W2949859621 hasConceptScore W2949859621C142724271 @default.
• W2949859621 hasConceptScore W2949859621C204787440 @default.
• W2949859621 hasConceptScore W2949859621C27081682 @default.
• W2949859621 hasConceptScore W2949859621C2776694085 @default.
• W2949859621 hasConceptScore W2949859621C2776755627 @default.
• W2949859621 hasConceptScore W2949859621C2777607594 @default.
• W2949859621 hasConceptScore W2949859621C2777866208 @default.
• W2949859621 hasConceptScore W2949859621C2777938653 @default.
• W2949859621 hasConceptScore W2949859621C2778461978 @default.
• W2949859621 hasConceptScore W2949859621C2778714382 @default.
• W2949859621 hasConceptScore W2949859621C2779260929 @default.
• W2949859621 hasConceptScore W2949859621C2779263901 @default.
• W2949859621 hasConceptScore W2949859621C2779338263 @default.
• W2949859621 hasConceptScore W2949859621C2779878957 @default.
• W2949859621 hasConceptScore W2949859621C2780653079 @default.
• W2949859621 hasConceptScore W2949859621C2781442060 @default.
• W2949859621 hasConceptScore W2949859621C71924100 @default.
• W2949859621 hasIssue "S2" @default.
• W2949859621 hasLocation W29498596211 @default.
• W2949859621 hasOpenAccess W2949859621 @default.
• W2949859621 hasPrimaryLocation W29498596211 @default.
• W2949859621 hasRelatedWork W203548035 @default.
• W2949859621 hasRelatedWork W2173371792 @default.
• W2949859621 hasRelatedWork W2191453721 @default.

• next